Novel therapies for constipation

World Journal of Gastroenterology

Volumn 19, Issue 45, 2013, Pages 8247-8251

  Thayalasekeran, Sreedhari ^a   Ali, Hani ^a   Tsai, Her Hsin ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Constipation; Linaclotide; Prucalopride

Indexed keywords

CHLORIDE CHANNEL; CYCLIC GMP; LINACLOTIDE; LUBIPROSTONE; PLACEBO; PRUCALOPRIDE;

ABDOMINAL PAIN; CONSTIPATION; DIARRHEA; DRUG SAFETY; DRUG TOLERANCE; HEADACHE; HUMAN; INTESTINE MOTILITY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NAUSEA; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC);

CONSTIPATION; LINACLOTIDE; PRUCALOPRIDE;

ALPROSTADIL; ANIMALS; BENZOFURANS; CALCIUM CHANNEL AGONISTS; CONSTIPATION; DEFECATION; ENZYME ACTIVATORS; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; PEPTIDES; SEROTONIN 5-HT4 RECEPTOR AGONISTS; TREATMENT OUTCOME;

EID: 84889569951     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i45.8247     Document Type: Review

References (29)

1. Peppas G, Alexiou VG, Mourtzoukou E, Falagas ME. Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol 2008; 8: 5 [PMID: 18269746 DOI: 10.1186/1471-230X-8-5]
2. Gray JR. What is chronic constipation? Definition and diagnosis. Can J Gastroenterol 2011; 25 Suppl B: 7B-10B [PMID: 22114751]
3. O'Donnell L, Virjee J, Heaton KW. Detection of pseudodiarrhea by simple clinical assessment of intestinal transit rate. Br Med J 1990; 300: 439-40 [DOI: 10.1136/bmj.300.6722.439]
4. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491 [PMID: 16678561 DOI: 10.1053/ j.gastro.2005.11.061]
5. Belsey J, Greenfield S, Candy D, Geraint M. Systematic review: impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther 2010; 31: 938-949 [PMID: 20180788 DOI: 10.1111/j.1365-2036.2010.04273.x]
6. Paré P, Bridges R, Champion MC, Ganguli SC, Gray JR, Irvine EJ, Plourde V, Poitras P, Turnbull GK, Moayyedi P, Flook N, Collins SM. Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment. Can J Gastroenterol 2007; 21 Suppl B: 3B-22B [PMID: 17464377]
7. Gonlachanvit S, Patcharatrakul T. Causes of idiopathic constipation in Thai patients: associations between the causes and constipation symptoms as defined in the Rome II criteria. J Med Assoc Thai 2004; 87 Suppl 2: S22-S28 [PMID: 16083156]
8. Lundin E, Karlbom U, Westlin JE, Kairemo K, Jung B, Husin S, Påhlman L, Graf W. Scintigraphic assessment of slow transit constipation with special reference to right-or leftsided colonic delay. Colorectal Dis 2004; 6: 499-505 [PMID: 15521943 DOI: 10.1111/j.1463-1318.2004.00694.x]
9. Rao SS, Sadeghi P, Batterson K, Beaty J. Altered periodic rectal motor activity: a mechanism for slow transit constipation. Neurogastroenterol Motil 2001; 13: 591-598 [PMID: 11903920 DOI: 10.1046/j.1365-2982.2001.00292.x]
10. Penning C, Steens J, van der Schaar PJ, Kuyvenhoven J, Delemarre JB, Lamers CB, Masclee AA. Motor and sensory function of the rectum in different subtypes of constipation. Scand J Gastroenterol 2001; 36: 32-38 [PMID: 11218237 DOI: 10.1080/00365520150218039]
11. Leung L, Riutta T, Kotecha J, Rosser W. Chronic constipation: an evidence-based review. J Am Board Fam Med 1999; 24: 436-451 [PMID: 21737769 DOI: 10.3122/jabfm.2011.04.100272]
12. World Gastroenterology Organisation. WGO practice guidelines: constipation.2007. Available from: URL: http:// www.worldgastroenterology.org/assets/downloads/en/ pdf/guidelines/05_constipation.pdf
13. Locke GR, Pemberton JH, Phillips SF. AGA technical review on constipation. American Gastroenterological Association. Gastroenterology 2000; 119: 1766-1778 [PMID: 11113099 DOI: 10.1053/gast.2000.20392]
14. Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic re-view. Am J Gastroenterol 2005; 100: 936-971 [PMID: 15784043]
15. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008; 358: 2344-2354 [PMID: 18509121 DOI: 10.1056/NEJMoa0800670]
16. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009; 58: 357-365 [PMID: 18987031 DOI: 10.1136/ gut.2008.162404]
17. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebocontrolled study. Aliment Pharmacol Ther 2009; 29: 315-328 [PMID: 19035970 DOI: 10.1111/j.1365-2036.2008.03884.x]
18. Quigley EM. Prucalopride: safety, efficacy and potential applications. Therap Adv Gastroenterol 2012; 5: 23-30 [PMID: 22282705 DOI: 10.1177/1756283X11423706]
19. Ke M, Zou D, Yuan Y, Li Y, Lin L, Hao J, Hou X, Kim HJ. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil 2012; 24: 999-e541 [PMID: 22882724 DOI: 10.1111/ j.1365-2982.2012.01983.x]
20. Potet F, Bouyssou T, Escande D, Baró I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel. J Pharmacol Exp Ther 2001; 299: 1007-1012 [PMID: 11714889]
21. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 2011; 60: 209-218 [PMID: 21205879 DOI: 10.1136/gut.2010.227132]
22. Liu LW. Chronic constipation: current treatment options. Can J Gastroenterol 2011; 25 Suppl B: 22B-28B [PMID: 22114754]
23. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007; 25: 1351-1361 [PMID: 17509103]
24. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008; 103: 170-177 [PMID: 17916109 DOI: 10.1111/ j.1572-0241.2007.01524.x]
25. Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 2010; 55: 1090-1097 [PMID: 20012484 DOI: 10.1007/s10620-009-1068-x]
26. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD, Shao JZ, Fitch DA, Baird MJ, Schneier HA, Johnston JM. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107: 1702-1712 [PMID: 22986437 DOI: 10.1038/ajg.2012.254]
27. Guidance for industry: irritable bowel syndrome-clinical evaluation of drugs for treatment. Food and Drug Administration 2012. Available from: URL: http://www.fda.gov/ downloads/Drugs/GuidanceComp-RegulatoryInformation/ Guidances/UCM205269.pdf.2013
28. Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, Eng P, Fox SM, Schneier HA, Kurtz CB, Johnston JM. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107: 1714-124; quiz p.1725 [PMID: 22986440 DOI: 10.1038/ ajg.2012.255]
29. Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, Shao JZ, Lavins BJ, Currie MG, Fitch DA, Jeglinski BI, Eng P, Fox SM, Johnston JM. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011; 365: 527-536 [PMID: 21830967 DOI: 10.1056/NEJMoa1010863]